Continuous hyperfractionated accelerated radiotherapy – Escalated dose (CHART-ED): A phase I study
Matthew Q F Hatton, Robert Graham Hill, John D. Fenwick et al. · Radiotherapy and Oncology · 2015
Cited by 18 works. doi:10.1016/j.radonc.2015.11.015
Authors
- Matthew Q F Hatton
- Robert Graham Hill
- John D. Fenwick
- Sally A. Morgan
- Paula Wilson
- Philip James Atherton
- Jeanette Dickson
- Kirsten Eleanor Murray
- James Paul
References
- Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group
- Comparing different NTCP models that predict the incidence of radiation pneumonitis
- A new approach to dose escalation in non–small-cell lung cancer
- Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial
- High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non–small-cell lung cancer: Long-term results of a radiation dose escalation study
- Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
- Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis